First quarter 2019 results presentation

Operating income, growth figures, profitability and how our products have behaved


No votes yet
 
Related
Today, Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the conclusion of the PRISMA-3 and BORIS  studies, thus...
5 min
05/07/2019
The López-Belmonte family, the principal shareholders of Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”), have increased their interest in...
1 min
27/05/2019
The operating revenue of Laboratorios Farmacéuticos ROVI increased by 8% to 82.2 million euros in the first quarter of 2019, mainly driven...
5 min
08/05/2019